VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preclinical Study Data Show Drug Combo’s Innovative Potential in Fight Against Major Depressive Disorder
Study results have exciting therapeutic potential across wide range of CNS indications. VTGN focused on developing new generation of medications to treat anxiety, depression and more. Company committed to finding treatment to help estimated 264 million people around the world who suffer from depression. Noting that 17.3 million adults in the United States have had at least one major depressive episode and some 264 million people around the world suffer from depression, VistaGen Therapeutics (NASDAQ: VTGN) is committed to finding effective treatments for depression that reach beyond the current standard of care, which includes oral antidepressants and oral atypical antipsychotics.…











